Episode 98: Xtandi for Metastatic & High-Risk Nonmetastatic Castration-Sensitive Prostate Cancer

Dr. Aaron Berger discusses the crucial role of treatment intensification with Xtandi (enzalutamide) for patients with metastatic castration-sensitive prostate cancer (mCSPC) and those with nonmetastatic castration-sensitive prostate cancer (nmCSPC) experiencing biochemical recurrence at high risk for metastasis. He emphasizes that Xtandi, an androgen receptor inhibitor, offers a significant therapeutic advantage by impeding the androgen receptor signaling pathway, which is essential for the growth of prostate cancer cells. For patients with mCSPC, incorporating enzalutamide into their treatment regimen can markedly slow disease progression, reduce the risk of new metastases, and improve overall survival rates. This strategic intervention allows for better disease control and enhances the quality of life for patients undergoing treatment. In addressing nmCSPC patients with biochemical recurrence, Dr. Berger highlights the importance of early and aggressive treatment to prevent the transition to metastatic disease. Elevated prostate-specific antigen (PSA) levels in these patients, despite castration, indicate a high likelihood of imminent metastasis. Dr. Berger advocates for the use of Xtandi in these scenarios to manage and stabilize PSA levels, thereby delaying the onset of metastasis. This proactive approach not only extends the window for effective long-term management but also aligns with a personalized treatment strategy that can significantly improve patient outcomes. Dr. Berger's expertise underscores the transformative impact of enzalutamide in managing advanced prostate cancer, providing a beacon of hope for patients through improved survival and disease management. *The expert's opinions in this communication are personal and not representative of any organization. They are for informational purposes only, not official guidance. Viewers are advised to use their judgment, seek additional advice, and take responsibility for any actions based on these opinions. #prostatecancer